Marik PE. Pharmacologic strategies for the treatment of acute respiratory distress syndrome: the horizon is getting closer.
Copyright © 2002 Sage Publications
Acute respiratory distress syndrome (ARDS), first described by Petty et al [1] in 1967, is a syndrome characterized by diffuse pulmonary infiltrates, with decreased pulmonary compliance and hypoxemia. More recently, it has become recognized that ARDS is a spectrum varying from mild acute lung injury (ALI) at one end to ARDS at the other [2] . ALI and ARDS (hereafter referred to as ARDS) are currently among the most common causes of respiratory failure in the intensive care unit [3] . The acute phase of ARDS is characterized by the influx of proteinrich edema fluid into the air spaces as a consequence of increased permeability of the alveolarcapillary barrier. Attempts at modulating the acute lung injury of ARDS with a host of pharmacologic agents including corticosteroids, antioxidants, inhibitors of thromboxane and leukotrienes, prostaglandin E1, pentoxifylline, anticytokines, and exogenous surfactant, to name but a few, have met with universal failure [4] . Thus, despite extensive investigation over the past 3 decades, the current management of ARDS is largely supportive [4, 5] .
Clinical and experimental studies have provided circumstantial evidence of the occurrence of neutrophil-mediated injury in ARDS [6, 7] . Patients with neutropenia are at a reduced risk of developing ARDS, with the risk increasing with recovery of the neutropenia [8, 9] . Histologic studies of lung specimens obtained early in the course of the disorder show a marked accumulation of neutrophils [10] . Neutrophils predominate in the pulmonary edema fluid and bronchoalveolar lavage fluid obtained from affected patients, and many animal models of acute lung injury are neutrophil dependent [6, 7] . In this issue of the Journal of Intensive Care Medicine, Kinoshita et al [11] measured various inflammatory mediators including neutrophil-related mediators in the serum of 47 patients with gram-negative sepsis who were admitted to their surgical intensive care unit. These authors demonstrated that the patients who developed ARDS had significantly higher levels of interleukin-8 (IL-8), macrophage inflammatory peptide-1-alpha, soluble intercellular adhesion molecule-1, and neutrophil elastase than the non-ARDS group. It is interesting to note that despite having higher levels of neutrophil-related mediators, the circulating neutrophil count was lower in the ARDS than in the non-ARDS group. This suggests an increase in the marginating pool of neutrophils in the ARDS group (ie, increased neutrophil aggregation and adhesion in the microcirculation). The results of this study are similar to those of Groeneveld et al [12] and Endo et al [13] , who demonstrated a strong relationship between the severity of the oxygenation defect and the IL-8 and neutrophil elastase levels in patients with ARDS and septic shock.
In the early stages of acute lung injury, proinflammatory mediators are released and function to prime circulating neutrophils and increase the expression of adhesion molecules, causing sequestration of neutrophils within the pulmonary vasculature. Sequestered neutrophils are then activated to release potent effector molecules including oxygen free radical species and proteases [14] . The recruitment of neutrophils is directed by a number of chemokines, particularly IL-8 [15, 16] . IL-8 is produced by a variety of cells including monocytes, macrophages, and endothelial cells. Tumor necrosis factor-alpha, IL-1, and endotoxin induce the release of IL-8 by these cells. IL-8 shows remarkable specificity for neutrophils and basophils. IL-8 has chemoattractant activity and is able to induce degranulation and elicit a respiratory burst in neutrophils.
The neutrophil-mediated proteases, neutrophil elastase, and the neutrophil matrix metallopro-teinases (MMPs) are believed to be the terminal effectors of neutrophil mediated lung injury [17] . These elastases are capable of degrading numerous extracellular matrix proteins including collagen, elastin, fibrin, fibronectin, and laminin [14, 17] . They also degrade complement, cytokines, and protease inhibitors and convert xanthine dehydrogenase to xanthine oxidase [14] . The neutrophil proteases are inhibited by a number of endogenous protease inhibitors, including alpha-1-proteinase inhibitor, alpha-2-macroglobulin, and eglin C. The toxicity of neutrophil elastase is markedly enhanced by oxidants released from the neutrophil, partly due to the oxidative inactivation of the endogenous protease inhibitors [18] .
These data would suggest that inhibition of neutrophil activation and degranulation or neutralization of its proteases may be beneficial in the management of ARDS. Experimental studies have demonstrated that inactivation of IL-8 with a monoclonal antibody attenuates the acute lung injury induced by acid aspiration [19] [20] [21] . However, most research has focused on inhibition of the neutrophil proteases, as these are believed to be the terminal mediators of neutrophil-mediated lung injury.
Chemically modified tetracycline-3 (COL-3) is a synthetic, nonantibacterial tetracycline derivative that is a potent inhibitor of both neutrophil elastase and MMPs. In animal models of ARDS, COL-3 has been demonstrated to reduce lung injury when given prior to the noxious insult [22, 23] . A number of other novel neutrophil elastase inhibitors, including TEI-8362 and ICI 200-355, have been demonstrated to attenuate lung injury in animal models [24, 25] . There is, however, limited clinical data on the safety and efficacy of these agents.
Sivelestat is a small molecular weight (434 Da) reversible, competitive inhibitor of neutrophil elastase that is stable in vitro in the presence of oxidants. In animal models of ARDS, sivelestat treatment attenuates lung injury [26, 27] . Unlike models of ARDS and sepsis in which the anti-inflammatory agent demonstrated a benefit when given prior to but not after the noxious insult, sivelestat has been demonstrated to cause a dose-dependent reduction in acute lung injury when given after aerosolized endotoxin [28] . These promising results are supported by a double-blind randomized clinical trial that compared high-dose with low-dose sivelestat in patients with systemic inflammatory response syndrome [29] . In this study, 72% of patients in the high-dose group demonstrated a moderate or marked clinical improvement compared to 56% in the low-dose group (P = 0.003). Sivelestat has been licensed by Eli Lilly, and currently a phase 2 multicenter trial in patients with ARDS is in progress. Sivelestat and other neutrophil protease inhibitors hold promise for the pharmacologic treatment of patients with ARDS, and hopefully should be available in the not too distant future.
